


## LBA-3

Cat. No.:	HY-158160
CAS No.:	2918263-09-7
Molecular Formula:	C <sub>18</sub> H <sub>18</sub> O <sub>5</sub>
Molecular Weight:	314.33
Target:	Sodium Channel
Pathway:	Membrane Transporter/Ion Channel
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	LBA-3 is a selective, orally active inhibitor for sodium-coupled citrate transporter SLC13A5, with an IC <sub>50</sub> of 67 nM. LBA-3 decreases levels of triglyceride and total cholesterol in oleic and palmitic acid (OPA)-stimulated AML12 cells, PCN-stimulated primary mouse hepatocytes and in mouse models, without detectable toxicity. LBA-3 is blood-brain barrier permeable <sup>[1]</sup> .
<b>In Vivo</b>	LBA-3 (50 mg/kg, po, single dose) exhibits a pharmacokinetic profile in Sprague Dawley rats, with peak plasma concentration C <sub>max</sub> of 288 262.00 µg/L, AUC of 704 570.43 h·µg-1·L and an oral bioavailability of 48.67% <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Zhang L, et al., Discovery of Highly Potent Solute Carrier 13 Member 5 (SLC13A5) Inhibitors for the Treatment of Hyperlipidemia. J Med Chem. 2024 Apr 25;67(8):6687-6704.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA